Drug Profile
Bupropion/dextromethorphan - Axsome Therapeutics
Alternative Names: AUVELITY; AXS-05; Dextromethorphan-HBr-bupropion-HCl; Dextromethorphan/bupropion; Dextromethorphan/bupropion modulated delivery tabletLatest Information Update: 08 Jan 2024
Price :
$50
*
At a glance
- Originator ANTECIP BIOVENTURES
- Developer Axsome Therapeutics; Duke University
- Class Anti-inflammatories; Antidementias; Antidepressants; Behavioural disorder therapies; Morphinans; Propiophenones; Small molecules; Smoking cessation therapies
- Mechanism of Action Adrenergic receptor antagonists; Cytochrome P 450 CYP2D6 inhibitors; Dopamine uptake inhibitors; Nicotinic receptor antagonists; NMDA receptor antagonists; Norepinephrine plasma membrane transport protein inhibitors; Serotonin plasma membrane transport protein inhibitors; Sigma-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Major depressive disorder
- Phase III Agitation
- Phase II Smoking withdrawal
Most Recent Events
- 04 Jan 2024 Axosome Therapeutics plans a pivotal phase II/III trial for Smoking withdrawal in 2024
- 27 Feb 2023 Axosome Therapeutics receives feedback from the FDA for AXS 05 in Alzheimer's disease for clinical development program
- 27 Feb 2023 Axosome Therapeutics announces intention to submit NDA for Agitation associated with Alzheimer's disease